Scalper1 News
Big pharma Merck reported stellar results for its phase-two hepatitis C (HCV) drug trials Thursday, sparking debate among analysts over its potential to take market share from leader Gilead Sciences. At the International Liver Congress in London, Merck (MRK) reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two potentially combined in one pill Scalper1 News
Scalper1 News